| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from ADAG graph: us to further compliance risk. Given the variability and evolving state of these laws, we face uncertainty as to the e… |
| MRK |
Merck & Co., Inc. |
72%
|
us to further compliance risk. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implem… |
| SNYNF |
Sanofi |
72%
|
age research and all clinical, product development and commercialization activities. Under the Sanofi Agreement, the Group granted Sanofi an exclusive, worldwide, sublicensable license to research, d… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ADAG graph: age research and all clinical, product development and commercialization activities. Under the Sanofi Agreement, the… |
| ADAGENE-INCORPORATED |
ADAGENE-INCORPORATED |
62%
|
, 2025. The warranty liabilities represent warrants we issued to a consultant at nil cash consideration as compensation for the consultant’s services in the field of investor relations and business d… |
| CAYMAN-LIMITED |
CAYMAN-LIMITED |
62%
|
us to further compliance risk. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implem… |
| EXPORTING-HUMAN-GENETIC-RESOURCES |
EXPORTING-HUMAN-GENETIC-RESOURCES |
62%
|
eric drug application and imported drug application. Drugs are classified into chemical drugs, biological products and traditional Chinese medicine or natural drugs. When Phases I, II and III clinica… |
| HOLDING-COMPANY-STRUCTURE-ADAGENE-INC |
HOLDING-COMPANY-STRUCTURE-ADAGENE-INC |
62%
|
t loss attributable to ordinary shareholders and non-GAAP net loss per ordinary share for the year. Reconciliation of GAAP and Non-GAAP Result For the years ended December 3… |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
us to further compliance risk. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implem… |
| HUMAN-GENETIC-RESOURCES |
HUMAN-GENETIC-RESOURCES |
62%
|
eric drug application and imported drug application. Drugs are classified into chemical drugs, biological products and traditional Chinese medicine or natural drugs. When Phases I, II and III clinica… |
| JSR-LIMITED |
JSR-LIMITED |
62%
|
nders. These institutional investors will continue have a significant level of influence because of their level of ownership, including a greater ability than you and our other shareholders to influe… |
| MA-1308-ONCO-C4-INC |
MA-1308-ONCO-C4-INC |
62%
|
en if we are successful in any such litigation, we may be required to incur significant costs and dedicate significant personnel time in defending such litigation. For more information on these and o… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
us to further compliance risk. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implem… |
| PLAN-ADAGENE-INC |
PLAN-ADAGENE-INC |
62%
|
o employment agreements with each of our executive officers. Each of our executive officers is employed for a period of twelve months, which will be renewed automatically and extended automatically f… |
| SHARE-INCENTIVE-PLAN-ADAGENE-INC |
SHARE-INCENTIVE-PLAN-ADAGENE-INC |
62%
|
o employment agreements with each of our executive officers. Each of our executive officers is employed for a period of twelve months, which will be renewed automatically and extended automatically f… |
| SUZHOU-CO-LTD |
SUZHOU-CO-LTD |
62%
|
en if we are successful in any such litigation, we may be required to incur significant costs and dedicate significant personnel time in defending such litigation. For more information on these and o… |
| SUZHOU-LIMITED |
SUZHOU-LIMITED |
62%
|
us to further compliance risk. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implem… |
| TAKING-SUCH-RESOURCES |
TAKING-SUCH-RESOURCES |
62%
|
eric drug application and imported drug application. Drugs are classified into chemical drugs, biological products and traditional Chinese medicine or natural drugs. When Phases I, II and III clinica… |
| UNITED-STATES-ADAGENE-INC |
UNITED-STATES-ADAGENE-INC |
62%
|
se, if approved; ● future strategic arrangements and/or collaborations and the potential benefits of such arrangements; ● our anticipated use of our existing resources and the proceeds from our initi… |
| UNITED-STATES-ADAGENE-INCORPORATED |
UNITED-STATES-ADAGENE-INCORPORATED |
62%
|
us to further compliance risk. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implem… |
